TY - CHAP M1 - Book, Section TI - Mitral Stenosis A1 - Bahl, Vinay K. A1 - Math, Ravi S. A2 - Fuster, Valentin A2 - Narula, Jagat A2 - Vaishnava, Prashant A2 - Leon, Martin B. A2 - Callans, David J. A2 - Rumsfeld, John S. A2 - Poppas, Athena PY - 2022 T2 - Fuster and Hurst's The Heart, 15e AB - Chapter SummaryThis chapter discusses the etiology, pathogenesis, clinical presentation, diagnostic modalities, and therapeutic options of mitral stenosis (MS). Rheumatic MS remains prevalent in developing countries whereas prevalence of degenerative MS has increased in developed countries. The hemodynamic hallmark of MS is a persistent diastolic gradient between the left atrium and left ventricle. Exertional dyspnea develops after a long asymptomatic latent period. The course is subsequently complicated by heart failure, atrial fibrillation, thromboembolism, and hemoptysis. Echocardiography is the mainstay of diagnosis, although cardiac catheterization may be needed to establish the severity in doubtful cases. While medical therapy can relieve the symptoms of MS, relief of the mechanical obstruction is needed to correct the underlying hemodynamic abnormality. This is achieved by balloon mitral valvotomy or mitral valve replacement in those with favorable or unfavorable anatomy, respectively. In patients with degenerative MS, newer therapies in the form of percutaneous transcatheter mitral replacement are being evaluated. A concerted global effort to control rheumatic heart disease is needed to reduce the prevalence of rheumatic MS. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/04/20 UR - accesscardiology.mhmedical.com/content.aspx?aid=1202446249 ER -